Adaptive Biotechnologies Corporation (ADPT)
Automate Your Wheel Strategy on ADPT
With Tiblio's Option Bot, you can configure your own wheel strategy including ADPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADPT
- Rev/Share 1.2703
- Book/Share 1.275
- PB 7.4824
- Debt/Equity 0.4564
- CurrentRatio 2.921
- ROIC -0.3203
- MktCap 1450807350.0
- FreeCF/Share -0.5949
- PFCF -16.3462
- PE -10.0454
- Debt/Assets 0.1701
- DivYield 0
- ROE -0.6609
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ADPT | Goldman | Neutral | Buy | -- | $9 | March 21, 2025 |
News
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Read More
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Read More
Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Founder Kyle Piskel - CFO Susan Bobulsky - Chief Commercial Officer Sharon Benzeno - Chief Commercial Officer of Immune Medicine Harlan Robins - Co-Founder & Chief Scientific Officer Conference Call Participants Andrew Brackmann - William Blair Rachel Vatnsdal - JPMorgan Mark Massaro - BTIG Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome …
Read More
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.
Read More
About Adaptive Biotechnologies Corporation (ADPT)
- IPO Date 2019-06-27
- Website https://www.adaptivebiotech.com
- Industry Biotechnology
- CEO Mr. Chad M. Robins M.B.A.
- Employees 619